PRIMARY STUDY
Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies
Key Findings: This review looks at the role of the endocannabinoid system in gastro-inflammatory diseases and possible cannabinoid therapeutics to treat them. It concludes that current data is lacking robust information, but suggests that further investigation of cannabinoid receptor (CBR) agonists, inhibitors of the reuptake of AEA and 2-AG, and inhibitors of endocannabinoid enzyme degradation are warranted as potential therapeutic targets in the management of gastro-inflammatory diseases.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Brazil
Year of Pub: 2022
Cannabinoids Studied: Cannabichromene (CBC), Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), CP-x Synthetic Cannabinoids, AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), N-Arachidonoyl Dopamine (NADA), Endocannabinoid (unspecified), Cannabidivarin (CBDV), Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2, GPCR
Ligands Studied: Acetylcholine, Anti-inflammatory cytokines, Dopamine, Pro-inflammatory cytokines
